Valuation: Applied Therapeutics, Inc.

Market Cap 1.52Cr 1.33Cr 1.23Cr 1.14Cr 2.16Cr 144.7Cr 2.2Cr 15Cr 5.73Cr 71Cr 5.72Cr 5.6Cr 246.83Cr P/E 2023
-2.36x
P/E 2024 -1.13x
Enterprise Value -6.14Cr -5.37Cr -4.95Cr -4.59Cr -8.71Cr -582.33Cr -8.85Cr -59Cr -23Cr -287.39Cr -23Cr -23Cr -993.35Cr EV / Sales 2023
2,09,74,366x
EV / Sales 2024 5,05,96,512x
Free-Float
95.24%
Yield 2023 *
-
Yield 2024 -
1 day+0.19%
6 months-2.83%
Current year+3.00%
Current year 0.09
Extreme 0.09
0.11
1 year 0.09
Extreme 0.09
1.5
3 years 0.09
Extreme 0.09
10.62
5 years 0.09
Extreme 0.09
22.27
10 years 0.09
Extreme 0.09
57.39
Manager TitleAgeSince
President - 03/02/2026
Corporate Secretary - 03/02/2026
Corporate Officer/Principal - 21/01/2025
Director TitleAgeSince
Director/Board Member - 03/02/2026
Date Insider Type Main position Quantity % Market Cap.
03/02Issuer sale

Director

3,93,053 0.2724%
03/02Issuer sale

Director

3,28,690 0.2278%
03/02Issuer sale

Director

3,28,690 0.2278%
Change 5-day change 1-year change 3-year change Capi.($)
+0.19%-.--%-67.81%-92.02% 1.57Cr
-0.10%+3.41%+73.88%+130.87% 5.77TCr
-3.80%-6.24%+67.04%+86.36% 5.47TCr
+0.38%+1.33%-14.32%-11.76% 2.38TCr
+1.17%+5.83%+16.39%+468.18% 2.42TCr
-2.70%+4.25%+40.38%-3.72% 1.98TCr
+3.78%+5.65%+44.99%-26.23% 1.71TCr
+3.46%+17.72%+206.66%+364.07% 1.68TCr
-1.81%+18.00%+41.99% - 1.56TCr
+2.79%+4.91%+29.26%+195.60% 1.4TCr
Average +0.34%+5.00%+43.85%+123.48% 2.44TCr
Weighted average by Cap. -0.40%+3.34%+57.81%+138.68%

Financials

2023 2024
Net sales 9.99 8.74 8.06 7.47 14.18 948.42 14.41 96.64 37.58 468.07 37.52 36.7 1.62T 0.46 0.4 0.37 0.34 0.65 43.18 0.66 4.4 1.71 21.31 1.71 1.67 73.66
Net income -12Cr -10Cr -9.66Cr -8.95Cr -17Cr -1.14TCr -17Cr -115.82Cr -45Cr -560.97Cr -45Cr -44Cr -1.94TCr -11Cr -9.24Cr -8.52Cr -7.9Cr -15Cr -1TCr -15Cr -102.14Cr -40Cr -494.74Cr -40Cr -39Cr -1.71TCr
Net Debt -4.91Cr -4.3Cr -3.96Cr -3.67Cr -6.97Cr -466.2Cr -7.08Cr -48Cr -18Cr -230.08Cr -18Cr -18Cr -795.25Cr -7.66Cr -6.7Cr -6.18Cr -5.73Cr -11Cr -727.03Cr -11Cr -74Cr -29Cr -358.81Cr -29Cr -28Cr -1.24TCr
Logo Applied Therapeutics, Inc.
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
Employees
28
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. APLT Stock